Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spruce BiosciencesSPRB -1.54%40 3-Year EBITDA Growth Rate is 29.60% as of Mar. 2026, which is 177% above its 10-year median of 10.70. GuruFocus rates SPRB with a GF Score™ of 40/100 and a GF Value™ of $4.08 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 1,135 Biotechnology companies, Spruce Biosciences ranks better than 66.78% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 29.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 27.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Spruce Biosciences was 36.70% per year. The lowest was -10.90% per year. And the median was 10.70% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Spruce Biosciences 3-Year EBITDA Growth Rate Related Terms
SPRB vs VXRT, VTVT, ENGN: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Spruce Biosciences's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spruce Biosciences 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spruce Biosciences's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Spruce Biosciences's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 29.60% mean?
Spruce Biosciences (SPRB) has a 3-Year EBITDA Growth Rate of 29.60% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Spruce Biosciences and its competitors. This is 177% above median its historical median of 10.70. According to the industry distribution chart, Spruce Biosciences ranks #377 out of 1135 companies in the Biotechnology industry, placing it in the top 33.2%.
Is Spruce Biosciences' 3-Year EBITDA Growth Rate too high?
Spruce Biosciences' current 3-Year EBITDA Growth Rate of 29.60% is 177% above median its 10-year median of 10.70. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Spruce Biosciences' value of 29.60% is 98.7% above this industry median. Based on the distribution chart, Spruce Biosciences ranks #377 out of 1135 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Spruce Biosciences has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spruce Biosciences' 3-Year EBITDA Growth Rate compare to VXRT and VTVT?
According to the Biotechnology industry distribution chart, Spruce Biosciences ranks #377 out of 1135 companies for 3-Year EBITDA Growth Rate. This puts Spruce Biosciences in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.90. Spruce Biosciences' value of 29.60% is 98.7% above this benchmark. While the company's 10-year median is 10.70 vs. the industry median of 14.90, Spruce Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,135 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Spruce Biosciences's current 3-Year EBITDA Growth Rate of 29.60% is 98.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Spruce Biosciences and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spruce Biosciences's current 3-Year EBITDA Growth Rate is 29.60%, which is 177% above median its own 10-year median of 10.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spruce Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Spruce Biosciences (SPRB) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.08, compared to a current price of $42.70 — trading 946.6% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 29.60%, which is 177% above median its 10-year median of 10.70 and 98.7% above the Biotechnology industry median of 14.90. Spruce Biosciences' overall GF Score™ is 40/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Spruce Biosciences (SPRB), the current 3-Year EBITDA Growth Rate is 29.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Spruce Biosciences (SPRB) Overvalued in 2026?
Based on GuruFocus' analysis, Spruce Biosciences stock appears to be overvalued.
The current stock price of $42.70 is trading 946.6% above its estimated GF Value™ of $4.08.
GuruFocus considers Spruce Biosciences to be Significantly Overvalued.
Key valuation signals for SPRB:
3-Year EBITDA Growth Rate: 29.60% (177% above median its 10-year median of 10.70)
GF Value™: $4.08 vs. price of $42.70 (946.6% above fair value)
Industry Position: 98.7% above the Biotechnology median (#377 of 1135)
No single metric tells the full story. See the SPRB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.
40GF Score
Get the complete analysis for SPRB
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SPRB has been successfully added to your 
